The application of phosphoramidate protide technology to acyclovir confers anti-HIV inhibition

Derudas, Marco, Carta, Davide, Brancale, Andrea, Vanpouille, Christophe, Lisco, Andrea, Margolis, Leonid, Balzarini, Jan and McGuigan, Christopher (2009) The application of phosphoramidate protide technology to acyclovir confers anti-HIV inhibition. Journal of Medicinal Chemistry, 52 (17). pp. 5520-5530. ISSN 0022-2623

Full text not available from this repository.

Abstract

Recently, it has been reported that phosphorylated acyclovir (ACV) inhibits human immunodeficiency virus type 1 (HIV-1) reverse transcriptase in a cell-free system. To deliver phosphorylated ACV inside cells, we designed ACV monophosphorylated derivatives using ProTide technology. We found that the l-alanine derived ProTides show anti-HIV activity at noncytotoxic concentrations; ester and aryl variation was tolerated. ACV ProTides with other amino acids, other than l-phenylalanine, showed no detectable activity against HIV in cell culture. The inhibitory activity of the prodrugs against herpes simplex virus (HSV) types -1 and -2 and thymidine kinase-deficient HSV-1 revealed different structure−activity relationships but was again consistent with successful nucleoside kinase bypass. Enzymatic and molecular modeling studies have been performed in order to better understand the antiviral behavior of these compounds. ProTides showing diminished carboxypeptidase lability translated to poor anti-HIV agents and vice versa, so the assay became predictive.

Item Type: Article
Schools and Departments: School of Life Sciences > Chemistry
Depositing User: Marco Derudas
Date Deposited: 28 Jul 2015 11:01
Last Modified: 28 Jul 2015 11:01
URI: http://sro.sussex.ac.uk/id/eprint/55777
📧 Request an update